May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Adverse events and lymphocyte activation in high–risk corneal and limbal grafts.
Author Affiliations & Notes
  • C. Sloper
    Queen's Medical Centre, Nottingham, United Kingdom
  • P. Radford
    Queen's Medical Centre, Nottingham, United Kingdom
  • H. Dua
    Queen's Medical Centre, Nottingham, United Kingdom
  • I. Todd
    Queen's Medical Centre, Nottingham, United Kingdom
  • R. Powell
    Queen's Medical Centre, Nottingham, United Kingdom
  • Footnotes
    Commercial Relationships  C. Sloper, None; P. Radford, None; H. Dua, None; I. Todd, None; R. Powell, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 610. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. Sloper, P. Radford, H. Dua, I. Todd, R. Powell; Adverse events and lymphocyte activation in high–risk corneal and limbal grafts. . Invest. Ophthalmol. Vis. Sci. 2004;45(13):610.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To test whether laboratory measurement of peripheral blood lymphocyte activation can be correlated with the clinical status of high–risk corneal and limbal grafts. Methods: Twenty patients with high–risk corneal and limbal grafts, receiving systemic immunosuppression with tacrolimus, were seen monthly for clinical assessment and serial blood samples. Adverse events identified were active new vascularisation of the graft, old vascularisation, epithelial disturbance, raised IOP, conjunctivitis and loose graft sutures. Samples from 36 age–matched normal subjects were analysed as controls. A stimulation assay was performed to measure the reactivity of peripheral blood lymphocytes to exogenous Interleukin–2, which was assessed by incorporation of tritiated thymidine. Each sample was divided into 8 aliquots, half of which were exposed to Interleukin–2. The stimulation index is the ratio of the IL–2 stimulated counts divided by the unstimulated counts. Results: The mean stimulation index for all patients was markedly reduced compared to controls (mean 18.07 c.f. 68.93; P < 0.0001, unpaired t–test). The stimulation index for grafts with active new vascularisation (mean 24.67) was increased both compared to baseline grafts with no adverse event (mean 15.80; P = 0.03, unpaired t–test) and those with inactive old vascularisation (mean 14.51; P = 0.04, unpaired t–test). On paired analysis, there was a significant difference between the stimulation indices at the time of an adverse event compared with the preceding baseline value (p < 0.01, paired t–test) and the subsequent baseline value in the same patient (p < 0.05, paired t–test). Conclusions: Changes in peripheral blood lymphocyte activation in high–risk corneal and limbal grafts, measured by stimulation assay, correlate with the clinical status of the grafts. These laboratory data may be helpful in making decisions regarding the duration of systemic immunosuppression.

Keywords: cornea: clinical science • transplantation • cornea: basic science 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×